In this case, nicknamed the MiraLax case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a settlement class of direct purchasers of Braintree’s branded drug, MiraLax (polyethylene glycol 3350). The case alleges that Braintree, to forestall competition from less-expensive generic versions of MiraLax, hatched an anticompetitive scheme that included a wrongful listing of a patent in the FDA Orange Book and sham litigation, thereby violating § 2 of the Sherman Act. The case alleges that Braintree’s scheme permitted it to charge Plaintiffs and members of the class artificially inflated prices for their purchases of brand and generic MiraLax. A settlement in the amount of $17.25 million was reached in 2012.
Faruqi & Faruqi, LLP
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Tel: (215) 277-5770
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.